Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Subcutaneous Rilpivirine LA Alone and With Cabotegravir LA in Healthy Participants
NCT05112939Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of rilpivirine in human immunodeficiency virus infection (HIV) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma Concentration of Rilpivirine (RPV) up to 72 weeks and Plasma Concentration of Cabotegravir (CAB) up to 72 weeks. Started Nov 2021; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05112939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112939.